CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2025	Jun. 30, 2024
Cash flows from operating activities
Net income (loss) attributable to common stockholders	$ 469	$ (10,384)
Adjustments to reconcile net income (loss) attributable to common stockholders to net cash used in operating activities:
Accrued final fee		111
Amortization of debt discount	381
Depreciation and amortization	773	798
Amortization of right-of-use asset	72	92
Write-off of patent cost		250
Write-off of inventory	253
Bad debt expense	9	29
Stock-based compensation	1,391	1,949
Foreign currency transaction (gains) losses	(9,192)	1,970
Changes in operating assets and liabilities
Grants and accounts receivable	257	(1,952)
Inventories	(925)	(1,030)
Prepaid expenses and other current assets	1,897	574
Other assets		1
Accounts payable and accrued expenses	(360)	(2,032)
Net cash used in operating activities	(4,975)	(9,624)
Cash flows from investing activities
Purchases of property and equipment	(39)	(63)
Payments for patent costs	(140)	(183)
Net cash used in investing activities	(179)	(246)
Cash flows from financing activities
Proceeds from long-term debt		15,000
Repayment of long-term debt		(5,000)
Payment of final fee		(150)
Payment of loan costs		(640)
Equity contributions - net of fees incurred		53
Proceeds from exercise of common stock warrants	1,439
Proceeds from rights offering, net of fees incurred	5,392
Net cash provided by financing activities	6,831	9,263
Effect of exchange rates on cash	285	(64)
Net change in cash, cash equivalents, and restricted cash	1,962	(671)
Cash, cash equivalents, and restricted cash at beginning of year	9,764	15,615
Cash, cash equivalents, and restricted cash - end of period	11,726	14,944
Supplemental disclosure of cash flow information
Cash paid for interest	1,018	538
Supplemental disclosure of non-cash financing activities
Warrants issued in connection with long-term debt	$ 556	$ 691